EGFR and neoplasm: For the 19 patients with, RAS/BRAF/EGFR mutant tumor, mPFS was 2.7 months (CI 95% 1.5–3.8) for 5 patients with grade 2–3 ST and 3.0 months (CI 95% 1.6–4.4) for 14 patients with grade 0–1 ST (HR, 1.93; CI 95%, 0.65–5.72; p = 0.23) (log-rank p = 0.008) (Figure 2, Figure S1 and Figure S2).